Tina Buch

Title: Tina Buch: Pioneer in Bispecific Antibody Development

Introduction: Tina Buch is an innovative inventor based in Efringen-Kirchen, Germany. With a strong background in biotechnology, she has made significant contributions to the field of immunotherapy. Her groundbreaking work has led to the development of a novel method for manufacturing bispecific antibodies, which are critical in targeted therapies for various diseases.

Latest Patents: Tina holds a patent titled "Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies." This invention pertains to the creation of bivalent bispecific monoclonal antibodies (bbmAb) and outlines methods for their production. The process involves co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines, enhancing the efficacy of treatment options available for patients.

Career Highlights: Tina is currently employed at Novartis AG, a leading global healthcare company known for its advancements in pharmaceuticals and biotechnology. Her work at Novartis has positioned her as a key player in the development of innovative therapeutic solutions, particularly in the realm of antibody engineering.

Collaborations: Throughout her career, Tina has collaborated with esteemed colleagues, including Michael Otto Bardroff and Christian Graf. These collaborations have fostered a dynamic research environment and have contributed to the advancement of their shared goals in biotechnology and immunotherapy.

Conclusion: Tina Buch stands out as a committed inventor whose work in bispecific antibodies is paving the way for future innovations in targeted therapies. Her patent and contributions at Novartis AG highlight her dedication to improving treatment options for patients, solidifying her role as a prominent figure in the field of biomedicine.